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ABSTRACT
The role of Thr729 in modulating the enzymatic
function of human topoisomerase I has been char-
acterized by molecular dynamics (MD) simulation. In
detail, the structural–dynamical behaviour of the
Thr729Lys and the Thr729Pro mutants have been
characterized because of their in vivo and in vitro
functional properties evidenced in the accompany-
ing paper. Both mutants can bind to the DNA sub-
strate and are enzymatically active, but while
Thr729Lys is resistant even at high concentra-
tion of the camptothecin (CPT) anti-cancer drug,
Thr729Pro shows only a mild reduction in drug sen-
sitivity and in DNA binding. MD simulations show
that the Thr729Lys mutation provokes a structural
perturbation of the CPT-binding pocket. On the
other hand, the Thr729Pro mutant maintains the
wild-type structural scaffold, only increasing its
rigidity. The simulations also show the complete
abolishment, in the Thr729Lys mutant, of the protein
communications between the C-terminal domain
(where the active Tyr723 is located) and the linker
domain, that plays an essential role in the control of
the DNA rotation, thus explaining the distributive
mode of action displayed by this mutant.
INTRODUCTION
Topoisomerases are a ubiquitous family of enzymes that
are essential for the cellular regulation of DNA super-
coiling, generated by processes such as replication,
transcription and recombination (1). Human topoisome-
rase I (hTop1p) is composed of 765 amino acids, arranged
in four domains: the NH2-terminal domain
(residues 1–214), the core domain (residues 215–635), the
linker domain (residues 636–712) and the COOH-terminal
domain (residues 713–765) (2,3). Changes in DNA topol-
ogy are achieved by introducing a transient break in the
phosphodiester bond of one strand in the duplex DNA,
and the formation of a transient covalent phosphotyrosine
bond between the catalytic Tyr723 and the 30-end of the
broken DNA strand (4). Relaxation of supercoiled DNA
is obtained by rotation of the scissile DNA strand around
the DNA intact one (5). After relaxation, the transient
bond between protein and DNA is broken and the
DNA strand is religated. The strict control of the rotation
step by the enzyme yields to a processive mechanism of
catalysis, i.e. the enzyme maintains the binding to a plas-
mid supercoiled DNA until complete relaxation, without
dissociation (5). If key protein regions involved in this step
are perturbed, as the linker and nose cone helices, the
enzyme carries out a distributive relaxation, i.e. it dissoci-
ates from the substrate after the release of only few super-
helical turns (6).
HTop1p is of signiﬁcant medical interest since it is the
only target of anti-cancer drugs, such as the camptothecin
(CPT) and its water-soluble derivatives. CPT is a plant
alkaloid that rapidly blocks both DNA and RNA synth-
esis, binding speciﬁcally and reversibly to the transient
covalent enzyme–DNA complex inhibiting the rotation
and religation steps of the catalysis. Collision between
the stabilized covalent complex intermediate and the repli-
cation fork results in double-strand DNA breaks and
triggers a cascade of event leading to apoptosis (7).
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from the active site, have been shown to render the
enzyme resistant to the CPT family drug (7). X-ray struc-
tures of hTop1p in complex with DNA and bound to
several anti-cancer agents have explained several aspects
of the mechanism of drug resistance (8–10).
The accompanying paper describes the eﬀect of
mutation on residue Thr729, located in helix 21 of
the C-terminal domain, to Ala, Glu, Lys or Pro (11).
The Thr729Ala mutant has been pointed by Kubota and
co-authors (12) as resistant to irinotecan in a human lung
cancer cell line. The same mutation, when expressed in
yeast Saccharomyces cerevisiae, does not show CPT resis-
tance that is achieved only when Thr729 is mutated
to Glu, Lys or Pro. Thr729Glu CPT resistance can be
explained by the strong inhibition of DNA binding and
enzymatic activity, while the structural/dynamic eﬀects on
the Thr729Lys mutant are more complex. The plasmid
relaxation activity, in fact, is comparable to that of the
wild-type enzyme, even though it shows a distributive
character, restored to a processive one in excess of sub-
strate, only. Mutation to Pro, ﬁnally, shows only a mild
reduction in CPT sensitivity and DNA binding, and a
relaxation activity comparable to the wild-type system,
with a functional processive mechanism.
In this article, we present a molecular dynamics (MD)
simulation of the wild type and two of these mutants,
Thr729Lys and Thr729Pro, in non-covalent complex
with a 22-bp DNA. Our analysis shows the essential role
of Thr729 in the protein long range communications func-
tional to the catalytic cycle, being helix 21 in interaction
with helices 16–17 in the core domain, helix 20 in the
C-terminal domain and helix 19 in the linker domain.
METHODS
The initial conﬁguration of hTop1p was modelled from
the 3D structure of the enzyme without the N-terminal
domain (topo70), in complex with a linear double helix
DNA substrate 22-bp long. In particular, the starting
positions for residues 215–633 and 641–765 were obtained
from the crystal structure 1a36 (5), and those for residues
203–214 from the crystal structure 1ej9 (13). The seven
residues constituting the loop region that connects the
linker to the core domain (residues 634–640, which are
lacking in the 1a36 PDB structure because of thermal
ﬂuctuation) were added to the system by molecular mod-
elling, as already described (14,15), using the SYBYL
program (St Louis, MO, USA). The same procedure has
been followed to reconstruct the partially missing side
chains of the residues not fully detected in the X-ray dif-
fraction structure. The spatial environment of each new
residue was checked for close contacts or overlaps with
neighbouring residues, and stereochemical regularization
of the structures was obtained by the Powell minimization
method implemented in the SYBYL program. Residue
729 has been changed from Thr to Lys and Pro to generate
the two mutant topo70–DNA complexes.
We used the GROMACS MD package version 3.3.1
(16) to carry out all the simulation, while modelling the
systems with the AMBER95 all-atom force ﬁeld (17).
The porting of the AMBER force ﬁeld in the
GROMACS code was implemented by Sorin and Pande
(18). The topo70–DNA complexes were placed in a
rectangular box (86 110 130 A ˚ 3) ﬁlled with TIP3P
water molecules (19), and rendered electro neutrals
by the addition of 21 Na
+ counterions, for the topo70
wild-type and Thr729Pro mutant, or 20 for the
Thr729Lys mutant, using the genion program of the
GROMACS package, that replaces solvent molecules by
ions at the position with the most favourable electrostatic
potential. The resulting total systems contained 9415 pro-
tein atoms, 1403 DNA atoms, 21 Na
+ counterions and 37
235 water molecules for topo70, giving a total of 122544
atoms; 9415 protein atoms, 1403 DNA atoms, 21 Na
+
counterions and 37302 water molecules for the
Thr729Pro mutant, giving a total of 122745 atoms; and
9423 protein atoms, 1403 DNA atoms, 20 Na
+ counter-
ions and 37302 water molecules for the Thr729Lys
mutant, giving a total of 122752 atoms. Optimization
and relaxation of solvent and ions were initially performed
keeping the protein and DNA atoms constrained to their
initial position with decreasing force constants of 1000
and 300kJ/(mol nm), for 300 ps. The systems were then
simulated for 13ns in periodic boundary conditions, at
a constant temperature of 300K using the Berendsen’s
method (20) and at a constant pressure of one bar; the
pressure was kept constant (1bar) using the Rahman-
Parrinello barostat (21) and with a 2fs time step.
Pressure and temperature coupling constants were 1 and
0.5ps, respectively. The electrostatic interactions were
taken into account by means of the Particle Mesh Ewald
method (22), using a cut-oﬀ radius of 0.9nm in real space,
while a cut-oﬀ radius of 1.2nm was chosen for the van der
Waals interactions. The lengths of all bonds were kept
constant with the Lincs algorithm (23). One nanosecond
of simulation of each system required 23h of wall clock
time on a server HP ProLiant DL585 G2, equipped with
four AMD Opteron 8220 SE Dual Core for a total of
8 cores at 2.8GHz each.
Thedynamiccross-correlation(DCC)mapsofthesystems
were built with in-house written codes, taking into account
only the coordinates of the 563 protein C-alpha atoms since
they contain enough information to describe the largest
system motions. The elements of the DCC map (Cij) were
computed as: Cij ¼ ri   rj
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ri is the displacement from the mean position of the i-th
atom and the hi represents the time average over the whole
trajectory. Positive Cij values represent a correlated motion
between residues i and j (i.e. the residues move in the same
direction).NegativevaluesofCijrepresentananti-correlated
motion between residues i and j (i.e. they move in opposite
directions). Direct hydrogen bonds, root mean square devia-
tions (RMSD) and ﬂuctuations (RMSF) have been carried
out using the GROMACS MD package version 3.3.1 (24).
The analyses reported in this article refer to the last
12ns of the trajectory (i.e. from 1ns to 13ns), since the
trend of the RMSD indicates that the systems are well
5646 Nucleic Acids Research, 2008, Vol. 36, No. 17stabilized after the ﬁrst nanosecond. In order to appreciate
the statistical convergence of the structural and dynamic
results, the average per-residue RMSF and DCC maps
analysed after 8ns of simulation (i.e. from 1ns to 8ns)
shown in Figures 11–13 in Supplementary data are to be
compared with Figures 1, 4 and 6, respectively, analysed
in the 1–13ns time window. The analyses are very similar,
indicating a substantial convergence of the simulations.
Figures 2, 3, 5 and 10 in Supplementary data were created
using the VMD visualization package (http://www.ks.
uiuc.edu/Research/vmd/; 25). Graphs have been obtained
with the Grace program (http://plasma-gate.weizmann.ac.
il/Grace/).
RESULTS
Mutation of residue 729in lysine orproline has anopposite
effect onthe fluctuations of human topoisomerase I
The per residue RMSF analysis (Figure 1) indicates that
the linker domain of the Thr729Pro mutant is less ﬂuctu-
ating (green line in Figure 1) when compared to the wild
protein and the Thr729Lys mutant (black and red lines,
respectively). Figure 1 also shows diﬀerences for the resi-
dues 601–615 ﬂuctuations (in the C-terminal region of the
core domain), being very high, intermediate and low for
the Thr729Lys mutant, wild-type and Thr729Pro mutant
simulations, respectively. Actually, the whole C-terminal
region of the core domain, the linker and the C-terminal
domain are less mobile in the Thr729Pro system, as com-
pared to the other two systems.
The average RMSD as a function of simulation time
have a similar behaviour among the three systems and
their amplitudes are similar to those obtained in other
simulations of the topo70–DNA complex (6,14), i.e. up
to 3A ˚ (data not shown). The mean RMSD values vary
between 1A ˚ and 2A ˚ after elimination of the linker domain
from the calculation, conﬁrming a high contribution of
this domain on the whole RMSD behaviour.
Interactions between helix 21 and helices 16, 17 and 20
Thr729 is located in the middle of helix 21 (residues
727–735 in the C-terminal domain, Figures 2A and 3A)
and its interactions with helices 16 (residues 586–606 in the
core domain), 17 (residues 612–629 in core domain) and
20 (713–722 in C-terminal domain) are fundamental for
a correct functioning of hTop1p (3). The catalytic residue
Tyr723, in fact, is located in the loop between helices 20
(residues 718–722) and 21 and several residues in this
region, such as Gly717, Thr718 and Asn722, have been
reported to modulate drug sensitivity and enzyme activity,
or produce a lethal phenotype in human or yeast topoi-
somerase I (14,26–28). In the wild-type protein, the only
direct helix 21–17 interaction is the hydrogen bond
between Thr729 and Tyr619 (Figure 2C), maintained for
the whole simulation time. Both the simulations of the two
mutated enzymes show the lack of this interaction, but the
structural and dynamical eﬀects are diﬀerent in the two
systems. Mutation of residue 729 in Lys, in fact, slightly
pulls away helix 17 from the N-terminal portion of helix
21, as observed plotting the distance between the C-alpha
atoms of Tyr619 and residue 729 as a function of simula-
tion time (Figure 7 in Supplementary data). However, the
most dramatic structural eﬀect caused by this mutation is
the occurrence of a new strong interaction between Lys729
and Lys720 that is present for the 80% of the simulation
time (Figure 2B). This interaction is never observed in the
other two simulations and it induces a conformational
perturbation of the drug-binding pocket, as evidenced
by the shortening of the Lys729–Asn722 distance when
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Figure 2. (A) Helix 17, in core domain, and helices 20 and 21, in the
C-terminal domain, are highlighted in red and light blue colours,
respectively. (B–D) Only the helices are shown in representative snap-
shots of the Tyr729Lys, wild-type and Tyr729Pro simulations, respec-
tively. The side chains of Lys720, in helix 20, of the mutated residue
729, in helix 21 and of Tyr619, in helix 17, are shown in ball and stick.
Stable direct hydrogen bonds, when present, are indicated with a
white line.
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Figure 1. Average per-residue RMSF represented as a function of the
residue number for the wild-type hTop1p protein (black line),
Tyr729Lys mutant (red line) and Tyr729Pro mutant (green line).
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mutant (Figure 8 in Supplementary data). Note that
Asn722, in the crystallographic structure of the ternary
topo70–DNA–topotecan complex (8), forms a water-
mediated hydrogen bond with the topotecan drug.
Moreover, mutation of Ans722 to Ala leads to hTop1p
drug resistance (29–31), while mutation to Ser, Asn or
His interferes with both enzyme activity and drug sensi-
tivity (27,32).
On the contrary, the Thr729Pro mutation induces a
slight reduction of the distance between helix 17 and the
N-terminal portion of helix 21 (Figure 7 in Supplementary
data), likely correlated with the larger rigidity of the
C-terminal portion of the core domain, the linker and
the C-terminal domain, as compared to the wild-type
and Thr729Lys mutant (Figure 1). Therefore, the
Thr729Pro mutation does not perturb the CPT-binding
site, being for instance the Pro729–Asp722 distance
identical to that in the wild type (Figure 8 in
Supplementary data).
Helix 16 takes part to the hTop1p active site with
Arg590 and it forms several interactions with the DNA
intact strand (3). In the wild-type enzyme, helices 21 and
16 interact through a direct hydrogen bond between
Trp732 and Thr606 (Figure 3C). This interaction is main-
tained in the Thr729Pro mutant (Figure 3D), but not in
the Thr729Lys one (Figure 3B). The distance between the
C-alpha atoms of Thr606 and Trp732, in the Thr729Pro
mutant, is indistinguishable from that of the wild-type
protein (Figure 9 in Supplementary data), while it strongly
ﬂuctuates in the Thr729Lys system. Thr606 is located
in the C-terminal portion of helix 16 (Figure 10 in
Supplementary data), in the 601–615 region that strongly
ﬂuctuates in the Thr729Lys mutant simulation, but not
in the other two systems (Figure 1). Analysis of the
secondary structure along with the simulation time
shows a partial loss of secondary structure of the
C-terminal region of helix 16 in Thr729Lys mutant
enzyme (Figure 10B and C in Supplementary data).
A similar loss of secondary structure of the C-terminal
region of helix 16 is observed in the crystal structure of
the topo70–DNA covalent complex in the absence of
topotecan (PDB id 1K4S) (8), where the linker domain
is not detected for its high ﬂexibility. In contrast, in
the crystal structure of the ternary topo70–DNA–TPT
complex (PDB id 1K4T) (8), the linker is resolved and
the secondary structure of helix 16 is intact, indicating a
structural correlation between the drug-binding pocket,
the 601–615 region and the linker domain. Our data
propose a structural and dynamical interpretation for
the key role played by residue 729 in these long-range
protein communications.
Long-range effects of residue729 mutations on thehTop1p
dynamics
The global motions of the proteins have been investigated
by means of the DCC map that provides an aggregate
picture of the correlated motions occurring between pro-
tein residues. Highly positive peaks of the Cij elements of
the map (red, yellow and green in Figures 4 and 6), in fact,
are indicative of strong correlation in the movement of
residues i and j, while negative Cij values (dark and light
blue in Figures 4 and 6) indicate that the two residues
move along opposite direction (anti-correlated motion).
Comparison of the DCC maps for the wild-type and
Thr729Lys systems (Figure 4, lower right triangle and
upper left triangle, respectively) shows a dramatic
change in the protein dynamics. The linker domain in
the wild-type system, in fact, moves in a highly anti-
correlated way with both the C-terminal domain and the
C-terminal region of the core domain (Figure 4, rectangles
A1 and C1, respectively). Moreover, these two regions
have a strong correlated motion, one with the other
(Figure 4, rectangle B1). Mutation of residue 729 in Lys
completely abolishes these correlated and anti-correlated
motions (Figure 4, rectangles A2, B2 and C2). Therefore,
although the ﬂuctuations of the linker domain in the
Thr729Lys protein are not signiﬁcantly diﬀerent from
the wild type (Figure 1), its motion is randomic and it is
hindered to participate to the protein domain communica-
tions,characterizingtheenzymaticfunctionalityofhTop1p
(9,33), as also shown by the distributive mode of action
described in the accompanying paper (see Figure 6 of the
accompanying paper). The perturbation of the local inter-
actions around the mutation site (Figure 2A; and Figure 8
in Supplementary data) suggests that the uncoupling
of the correlated motions in the linker domain of the
Thr729Lys mutant is triggered by the lack of interactions
between helices 21–16 and 21–17, respectively (Figures 2
and 3). The linker domain, in fact, interacts with helix 17
Helix 21
Helix 16
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Figure 3. (A) Helix 16, in core domain, and helix 21, in the C-terminal
domain, are highlighted in red and light blue colours, respectively.
(B–D) Only the helices are shown in representative snapshots of the
Tyr729Lys, wild-type and Tyr729Pro simulations, respectively. The side
chains of Thr606 and Trp732, in helixes 16 and 17, respectively, are
shown in ball and stick. Stable direct hydrogen bonds, when present,
are indicated with a white line.
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domain also in the X-ray structures) in the three simula-
tions by means of several hydrophobic residues: Val703,
Ile714 and Leu716 in helix 19, and Pro613 and Leu617 in
helix 17 (Figure 5). Therefore, the helix 17 altered motion
in the Thr729Lys mutant, that is a consequence of its
diﬀerent interactions with helix 21, is directly transmitted
to the linker domain dynamics.
Comparison of the DCC maps for the wild-type and
Thr729Pro systems (Figure 6, lower right and upper left
triangles, respectively) shows the vanishing of the corre-
lated and anti-correlated motions already observed for the
Thr729Lys mutant (highlighted in Figure 6 by rectangles
A1, B1 and C1 in the wild-type system) and the appear-
ance of a new strong correlated motion among the linker
domain residues (highlighted in Figure 6 by circle A2).
All the regions involved in these interactions (i.e. the
C-terminal region of the core domain, the linker domain
and the C-terminal domain) show an increased rigidity in
the Thr729Pro mutant (Figure 1), likely responsible for
the reduction of correlated motions. An increase of anti-
correlated motion between the linker domain and the
region containing the nose cone helices 5 and 6 (in the
core sub-domain II and I, respectively) is also observed
(highlighted in Figure 6 by rectangle B2), indicating, in the
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Figure 4. Dynamic cross correlation map for the topo70 (lower right
triangle) and Tyr729Lys mutant (upper left triangle). Correlated values
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scale depending on the absolute value of the correlation. The value 1,
along the diagonal (correlation of the residue with itself), is represented
in black.
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Figure 5. (A) Helix 17, in core domain, and helix 19, in the linker
domain, are highlighted in red and green colours, respectively. (B–D)
Only the helices are shown in representative snapshots of the
Tyr729Lys, wild-type and Tyr729Pro simulations, respectively. The
side chains of Pro613, Leu617, Ala627, in helix 17, and Val703,
Ile714, Leu716, in helix 19, are shown in ball and stick.
Nucleic Acids Research, 2008, Vol. 36, No. 17 5649Thr729Pro mutant, a strong communication between the
two protein regions involved in the control of the DNA
strand rotation. This is in line with the experimental obser-
vation of a more processive mode of relaxation for this
mutant (see Figure 6 of the accompanying paper).
DISCUSSION
The experimental characterization of Thr729 mutations in
hTop1p, described in the accompanying paper, draws a
complex picture of the role of this residue in enzymatic
activity and drug sensitivity, since the four studied muta-
tions (Ala, Lys, Pro and Glu) exert diﬀerent behaviours.
Mutation of residue 729 to Ala does not signiﬁcantly alter
the in vivo and in vitro properties of the enzyme, when
compared to the wild type. Mutation to Glu shows
in vivo drug resistance (Figures 1 and 4 of the accompany-
ing paper), a strong reduction in DNA binding (Figure 7
of the accompanying paper) and thus a signiﬁcant reduc-
tion in DNA-relaxation activity (Figures 2 and 6 of the
accompanying paper). Mutation to Lys induces CPT resis-
tance (Figures 1 and 4 of the accompanying paper), a
less dramatic reduction in DNA binding (Figure 7 of the
accompanying paper) and a DNA-relaxation activity
nearly comparable to that of the wild-type enzyme
(Figure 2 of the accompanying paper). In this mutant,
the relaxation mechanism is altered when tested in excess
of DNA substrate (Figure 6A of the accompanying
paper), and a mode of relaxation similar to wild type is
restored only when the reaction is carried out in excess of
enzyme (Figure 6B of the accompanying paper). Mutation
to Pro induces an intermediate behaviour between the
wild-type and the Thr729Lys mutant, showing a mild
reduction in drug sensitivity and in DNA binding
(Figures 1, 4 and 7 of the accompanying paper) and a
mode of relaxation similar to wild type also in excess of
DNA substrate (Figure 6A of the accompanying paper).
We have carried out a structural and dynamical char-
acterization of the two mutants, i.e. Thr729Lys and
Thr729Pro that experimentally maintain DNA binding
and relaxation activity while showing a large diﬀerence
in drug resistance.
MD simulation of the non-covalent hTop1p–DNA
complex with the single Thr729Lys mutation shows
a structural alteration of the drug-binding pocket pro-
voked by the loss of the 729–619 interaction and the
occurrence of the Lys729–Lys720 one (Figure 2B; and
Figure 8 in Supplementary data). The shortening of the
Lys729–Asn722 distance explains the experimentally
observed drug resistance of the Thr729Lys mutant, since
Asn722 in the wild-type enzyme forms a water-mediated
contact with the topotecan anti-cancer drug and its muta-
tion leads to hTop1 drug resistance (8,27,29–32).
Residue 729 plays an essential role in catalysis also. The
MD simulation of the wild-type enzyme shows how helix
21, containing the mutated residue, is involved in a net-
work of interactions between helices 21–16, 21–17 and
17–19, that mechanically couples the region controlling
the DNA rotation (the linker and the nose cone helices)
with the active site region. Mutation of residue 729 to Lys
abolishes these protein communications (Figure 4), giving
a rationale to the experimentally observed distributive
mechanism of DNA relaxation. These long-range eﬀects
are, in fact, triggered by the 729 mutation, through per-
turbation of the helix 21–helix 17 interaction that is trans-
mitted to both the drug-binding pocket (through helix
21–helix 20 interactions) and the linker domain (through
helix 17–helix 19 interactions).
On the contrary, the Thr729Pro mutation does not per-
turb the drug-binding pocket geometry, being the eﬀect of
the mutation opposite to that induced by the Thr729Lys
mutation, i.e. the geometrical arrangement of helices
21–16–17 is maintained while their dynamic motions are
reduced in amplitude, thus suggesting the structural
reason for its CPT sensitivity. Moreover, the linker
domain and nose cone helices show a strong increase in
correlation motion, demonstrating the eﬃciency of com-
munication in the protein region involved in the control of
DNA rotation, again in line with the experimental evi-
dence of the DNA-relaxation processivity.
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Supplementary Data are available at NAR Online.
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